Uncategorized

$AZRX Physical Fitness in Children is More Important Than BMI

new study by the University of Georgia has shown that while grown-ups exercise mostly to lose weight, children should exercise to build endurance, or how well their bodies can handle long periods of exercise. Physical education for children should be centered on motivating children to be active, educating them on the benefits of exercise and improving their physical skills.

According to the authors of the study, strengthening children’s cardiorespiratory endurance should be the main goal in exercise for children. Even children who are overweight can still achieve the recommended one hour of moderate to vigorous physical activity every day. The BMI of a person is measured to find out if he or she is overweight, obese or normal weight. The measurement is said to indicate that children who are more active in PE are more likely to remain active after school.

Lead author of the study, associate professor in the Mary Frances Early College of Education Sami Yli-Piipari, explained that the research had demonstrated that even in young children, those who are fitter with regard to cardiorespiratory endurance took part in more intense physical activities. He also stated that children who were a little overweight could still be relatively fit and that the weight didn’t really matter.

The study involved 450 kids, between the ages of 10-12, who participated in one and a half hours of mandatory physical education (PE) each week. During the day, the children wore an accelerometer on their right hip to record the total physical activity for a week. Additionally, simple tests, such as being able to do a crunch or a modified or regular push-up, were used to find out the children’s mastery of physical skills. The researchers also evaluated whether students took part in PE because it was mandatory or because they enjoyed it.

Yli-Piipari added that PE mattered, as the activities helped students not only learn skills but also presented them with the opportunity to do something active at a higher level than they normally might after the school day. The study was conducted in Finland, as students in that country have more time allotted to PE classes as their fellow American students. Finnish PE classes focus on the significance of exercise and how to include it into students’ daily activities.

As prior research had already shown, boys tended to be more active when compared to girls. Surprisingly though, motor skills and muscle strength did not depend on activity levels. The researchers discovered that motivation did not play a role in whether a student wanted to take part in PE or whether they enjoyed the PE classes. Those who were generally less active in their down time were found to be children who didn’t take part in after-school activities.

AzurRx BioPharma Inc. (NASDAQ: AZRX) is a biomedical company worthy of your attention. The company is in the business of using recombinant proteins to come up with novel treatments targeting gastrointestinal conditions.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Monday, November 16th, 2020 Uncategorized Comments Off on $AZRX Physical Fitness in Children is More Important Than BMI

HempFusion Wellness Builds Reputation for Safety in the Global CBD Market, Aims to IPO on TSX Exchange

  • HempFusion Wellness, Inc. is a health and wellness company developing the power of whole-food hemp nutrition through more than 40 products currently on store shelves
  • The company is focused on industry safety and quality standards through regulatory compliance, and is currently participating in a real world consumer study to establish the safety of daily cannabidiol (“CBD”) use in regard to liver function
  • HempFusion has filed a preliminary prospectus for a planned initial public offering of its stock in Canada and a listing on the Toronto Stock Exchange
  • Despite a reduction in hemp farm acreage this year following last year’s glut, market watchers anticipate the industrial hemp market is expected to reach $22 billion by 2022

The U.S. election this month demonstrated the lasting potential of the market for cannabis-derived products when five states joined the march toward legalizing marijuana for recreational or medicinal uses (https://nnw.fm/41UKq). Despite a variety of challenges that plagued the nascent hemp industry in 2019 as well as the contentious societal debates over the COVID-19 pandemic’s impact on everyday life and the choices for president, cannabis’ hemp and marijuana offshoots seem to have transcended the upheaval that has defined 2020.

Denver-based HempFusion Wellness has continued to build its own movement toward market success in the cannabis wellness industry, developing 46 products that are currently on shelves while establishing the second-largest cash position in its sector without debt. And in October the company announced a preliminary prospectus with the securities regulatory authorities in Canada, excepting the Quebec province, for a proposed initial public offering of common shares and listing on the Toronto Stock Exchange that makes HempFusion the first US-based cannabidiol (“CBD”) company to apply to list on the TSX (https://nnw.fm/LTOfk).

HempFusion Wellness has invested heavily in regulatory compliance in order to meet and exceed the safety and quality standards established not only by government officials, but selective consumers and retailers as well. As a member of the U.S. Hemp Roundtable, the company works with other coalition members in advancing the safety of hemp and CBD products.

The company’s focus on regulatory compliance has in turn opened doors to major food and drug mass market retailers. HempFusion has its eye on five channels — natural health retail outlets, Internet-based commerce, big box chains and other mass markets, doctor / care provider referrals and convenience stores.

HempFusion’s proprietary Whole Food Panoramic Full-Spectrum Hemp Complex products present solutions for basic, specific needs such as sleep, energy and stress. Its offerings include tinctures and capsules, as well as FDA listed over-the-counter (“OTC”) products designed to combat pain, eczema, acne and skin aging, and wounds.

HempFusion is one of 12 companies working to capture real world evidence from consumers on how they use CBD products and how their bodies react to those products, with a primary focus on whether daily use is safe for the liver in response to questions raised by the U.S. Food and Drug Administration (https://nnw.fm/C5axg).

“We believe this real world evidence is important to the FDA and could be used to guide policy moving forward,” Patrick McCarthy, the CEO of life sciences researcher ValidCare, which is conducting the scientific study, stated.

Licensed hemp farm acreage decreased on a year-over-year basis in 2020 for the first time since the 2014 Farm Bill established a national hemp pilot program, according to industry watchers (https://nnw.fm/y3z2h). The downward movement was driven by regulatory uncertainty and a vast oversupply of hemp last year in the wake of the previous winter’s updating of the 2014 bill to provide broader legalization to hemp as an agricultural commodity. It is important to note, HempFusion is not a cultivator and is instead focused on product R&D, increased distribution and consumer safety. Nevertheless, Brightfield Group has projected the hemp CBD market to reach $22 billion by 2022 (https://nnw.fm/3Z5Fi).

For more information, visit the company’s website at www.HempFusion.com/Corporate-Information.

NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://nnw.fm/HempFusion

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Monday, November 16th, 2020 Uncategorized Comments Off on HempFusion Wellness Builds Reputation for Safety in the Global CBD Market, Aims to IPO on TSX Exchange

Knightscope, Inc.’s AI-equipped Security Robots Building Confidence in Law Enforcement Sector

  • Knightscope is building a clientele for its robotic security force models, including about dozens of clients from Fortune 1000 companies, to law enforcement agencies, hospitals, casinos, water utilities, malls and manufacturing plants
  • The company’s robots use artificial intelligence to navigate indoor and outdoor areas that are Americans with Disabilities Act compliant, and can be monitored with a simple browser and Internet connection
  • The robots record data and use recognition features to assess potentially significant elements such as human activities, thermal changes and license plate information
  • The privately held company is backed by more than 16,000 investors and four major corporations, and has raised more than $70 million since its founding in 2013
  • Knightscope has now secured its first agreement with the federal government for a project at a Texas Veterans Administration hospital, which the company hopes may lead to more federal projects in the future

A series of publicized incidents in which police officers used violence against racial minorities during the past few years, generating controversy because of their tactics, has led to a nationwide debate about the role of law enforcement and the potential need for police reform.

The debate has extended beyond the purview of street-patrolling officers in metropolitan areas, as demonstrated by the recent announcement from the University of Oregon that it will convert several vacant armed police officer positions into frontline, unarmed community service officer positions — an effort to develop more confidence in campus security forces while retaining a backup armed police presence for potentially violent circumstances (https://nnw.fm/EFhQ7).

Autonomous Security Robot developer Knightscope is pursuing a distinct strategy for generating confidence in protective forces. The company’s roving, artificial intelligence-equipped sentries are designed to create a qualified security presence not unlike the one used at the university, presenting a non-threatening patrol that is nonetheless a capable, critical frontline deployment in combating criminal forces.

Knightscope’s indoor and outdoor-capable models feature 360-degree eye-level HD streaming video, speakers for recorded or live communication, and recognition features that detect people, faces, license plates, thermal fluctuations and automatic signals.

A whimsical CG-animated video of the robots arriving at a train station celebrates the company’s first deployment on behalf of the federal government with an agreement to use them at the Audie L. Murphy Memorial Veteran’s Hospital in San Antonio, Texas (https://nnw.fm/vNQTY). Knightscope is hopeful its performance there will lead to additional government projects in the future.

“One of the more obvious roles for robots in security is that they’re highly productive in repetitive and dangerous tasks,” Stacy Stephens, the vice president of marketing and sales, said in another video that explains how the robots work (https://nnw.fm/6qzhI). “So if you can imagine putting a human being into a place where they’re doing the same thing over and over and over again, they become ineffective very, very quickly. You can also imagine having to put somebody in the line of fire in a dangerous situation — a robot doesn’t care about that. You put them in there instead of a human being, you make it safer and much more productive.”

Human operators can then monitor and review the data the sentries collect at will. The robots function in Americans with Disabilities Act-compliant areas, using LiDAR for navigation in combination with sonar and GPS to navigate. They also retain video data for two weeks, which is accessible with a simple Chrome browser and Internet connection. Their mere presence may serve as a deterrent for problems.

The company estimates that the robots operate in a price range of about $4 to $11 an hour, which makes their service less expensive than their human counterparts after they’ve been purchased. Clients include about Fortune 1000 clients, such as Samsung and Citizens Bank, five major hospitals plus law enforcement agencies.

Using equity crowdfunding, Knightscope has raised millions of dollars to support its operations from a larger pool than most big money companies might seek and is now raising growth capital to scale up its operations.

“A lot of larger institutional investors will say, … ‘You have 7,000 investors, they must be driving you mad,’” CEO William Santana Li said during an interview earlier this year with StartEngine strategic adviser Kevin O’Leary, aka Mr. Wonderful (https://nnw.fm/0aRRS). “I tell them, ‘Listen, chief security officers of major corporations are investors of ours. NYPD detectives, FBI, CIA, DHS, vice presidents of leasing of major malls. I would never dare trade out our 7,000 investors for three or four guys (it’s mostly guys) sitting around a table asking the wrong questions, worried about all the wrong things.”

Knightscope is now backed by more than 16,000 investors and four major corporations, having raised more than $70 million since it began in 2013.

For more information, visit the company’s website at www.Knightscope.com.

Visit www.Knightscope.com/Invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO.

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://nnw.fm/Knight

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Monday, November 16th, 2020 Uncategorized Comments Off on Knightscope, Inc.’s AI-equipped Security Robots Building Confidence in Law Enforcement Sector

$VTGN Announces Q2 Results, Provides Update on CNS Pipeline and Business Progress

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today reported its financial results for the fiscal 2021 second quarter ended September 30, 2020. In addition, the company provided an update on its CNS pipeline and business progress. “We see a significant rise in mental health concerns as the global COVID-19 pandemic continues to impact the daily lives of millions of individuals. We are committed to developing innovative therapies that provide relief to those suffering from anxiety and depression, and we are working diligently towards that goal,” said VistaGen CEO Shawn Singh. “We are making significant progress in preparing PH94B for launch of a pivotal Phase 3 study for acute treatment of anxiety in adults with social anxiety disorder in the second quarter of 2021. After reaching consensus with the FDA on the key components of the study design, it will be very similar to the statistically significant Phase 2 study of PH94B in social anxiety disorder. We are also working with the FDA to finalize details for our Phase 2A study of PH94B in adjustment disorder, which we are planning to initiate in early 2021.”

To view the full press release, visit http://ibn.fm/c1QvN

About VistaGen Therapeutics

VistaGen is a clinical-stage biopharmaceutical company developing and commercializing differentiated new generation medicines that go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on TwitterLinkedIn and Facebook.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at http://ibn.fm/VTGN

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Friday, November 13th, 2020 Uncategorized Comments Off on $VTGN Announces Q2 Results, Provides Update on CNS Pipeline and Business Progress

$WTER to Host Teleconference to Discuss Q2 2021 Results

The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER), a producer of premium bottled alkaline and flavored-infused drinking waters and CBD-infused products, on Thursday announced its plans to host a teleconference with investors and analysts to review fiscal second-quarter 2021 financial results. President and CEO Richard Wright and Chief Financial Officer David Guarino will host the call at 5:00 PM Eastern Time on Monday, Nov. 16, 2020. In addition, the company will issue a press release outlining its financial results and outlook after the market close on Nov. 16, 2020. Interested parties may join the teleconference by dialing 877-407-3088 (U.S. and Canada) or 201-389-0927 (International / Outside of the U.S. and Canada). Participants are asked to dial in five to 10 minutes before the scheduled call time.

To view the full press release, visit: https://cnw.fm/HuHdy

About The Alkaline Water Company

Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in seven unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies. To learn more about the company, visit www.A88CBD.com and www.TheAlkalineWaterCo.com.

NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Friday, November 13th, 2020 Uncategorized Comments Off on $WTER to Host Teleconference to Discuss Q2 2021 Results

$SGLB Investor Summit Group Releases Lineup of 77 Public Companies to Present at Virtual Fall Event

The Investor Summit Group on Thursday released further details for its Virtual Fall Summit, which is slated to take place from Nov. 16-18, 2020. The event will connect 77 presenting small and microcap companies with distinguished investors from around the globe. Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF)Sigma Labs Inc. (NASDAQ: SGLB) and Trxade Group Inc. (NASDAQ: MEDS) are among the full list of companies scheduled to present at the Fall Investor Summit. Please refer to the update for a complete list of issuers, as well as webcasting links to view the presentations.

To view the full press release, visit http://ibn.fm/Ce9NL

About Investor Summit Group

The Investor Summit Group (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. Having produced successful conferences over the past five years, the upcoming event will be the third virtual edition added to Investor Summit’s growing portfolio where hundreds of high-quality meetings between executives and investors will take place over three days. The Investor Summit Group prides itself on building community and providing a platform for the industry and looks forward to launching new features at the upcoming Fall Summit such as virtual networking, panels and a stock pitch competition to promote endless connections in a virtual format. To register for the upcoming Investor Summit, visit www.InvestorSummitGroup.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Friday, November 13th, 2020 Uncategorized Comments Off on $SGLB Investor Summit Group Releases Lineup of 77 Public Companies to Present at Virtual Fall Event

$PCSA Announces Q3 2020 Results, Provides Corporate Update

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products intended to provide treatment for and improve the survival and/or quality of life for patients with unmet medical needs or no alternative treatment, on Thursday released its financial results for the third quarter of 2020. In addition, Processa provided a business update via conference call, for which the replay may be accessed at https://ibn.fm/BdxSB or by dialing 877-481-4010 (Toll-free) or 919-882-2331 (International) and entering replay passcode: 38528. “The third quarter was a period of tremendous value creation. Over that time, we in-licensed important clinical drug candidates PCS12852 and PCS6422, uplisted to Nasdaq and closed a $19.2 million public offering,” Dr. David Young, CEO and chairman of Processa, stated in the press release. “Due to those achievements, we now have sufficient funds to complete three trials for three distinct markets, each exceeding $1 billion. Importantly, we are developing products for which existing clinical evidence of efficacy has already been established. With key milestones to announce over the next 12-18 months, including interim data for PCS6422 in 3Q21 and PCS499 in 4Q21, we are excited about the near-term opportunity of increasing shareholder value.”

To view the full press release, visit http://ibn.fm/VpuUK

About Processa Pharmaceuticals Inc.

The mission of Processa is to develop products for which existing clinical evidence of efficacy has already been established for unmet or under-served medical conditions for which patients need treatment options that improve survival and/or quality of life. The company used these criteria to develop its pipeline programs in order to achieve high-value milestones effectively and efficiently using the Processa Regulatory Science approach. The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at http://ibn.fm/PCSA

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Friday, November 13th, 2020 Uncategorized Comments Off on $PCSA Announces Q3 2020 Results, Provides Corporate Update

$PCSA Biodegradable Implantable Sensors Can Monitor Body Functions

Using biodegradable materials, an international team of scientists has designed a flexible gas sensor that is highly sensitive and can be implanted in the human body. The sensor, which monitors a patient’s condition during and after medical procedures, biodegrades safely after its use has been exhausted and is absorbed by the body. This is a much better sensor than the sensors currently in use. The current sensors are not only expensive, but they can also be dangerous and uncomfortable.

Researchers designed this implantable sensor that can monitor different forms of nitrogen dioxide and nitric oxide gas in the body. These gases play a beneficial although sometimes harmful role in a person’s health, hence the need to monitor them. For instance, nitric oxide, which is a highly reactive gas produced in the human body naturally, widens or relaxes blood vessels, thus allowing nutrients and oxygen to circulate in the body, enhancing blood flow.

An assistant professor in the Department of Engineering Science and Mechanics at Penn StateDr. Huanyu Cheng, states that nitric oxide transforms into nitrogen dioxide when it’s exposed to oxygen and notes that environmental exposure to nitrogen dioxide is connected with the progression of conditions such as chronic obstructive pulmonary disease.

The study findings were reported in the “NPG Asia Materials.” The sensor was made from materials that weren’t just biodegradable but also stretchable. Cheng elaborated on how the team decided on its sensor design, explaining that devices currently being used are not as accurate as a device that was implanted; today’s devices are also bulky and are used outside the body. What few implantable devices available need to be removed, which may result in another operation.

According to the researchers, all the components used to make the sensors are biodegradable in bodily fluids and water but are still functional enough to record information on bodily gas levels. The sensor’s functional materials are made from silicon because it’s extremely sensitive to nitric oxide while its conductors are made out of magnesium. The materials are said to dissolve at a slow pace that allows the sensors to continue functioning in the patient’s body during their recovery period.

The sensor was tested in aqueous solutions and humid conditions to demonstrate that it could perform steadily in the body’s harsh conditions. The team of researchers note that in the future, they will work toward designing integrated systems that can monitor other body functions for various disease applications and for healthy aging.

An entity you need to pay attention to within the biomedical industry is Processa Pharmaceuticals Inc. (NASDAQ: PCSA). This firm specializes in identifying medical needs for which clinical efficacy proof exists regarding possible remedies. Processa then develops those remedies and brings them to market.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Friday, November 13th, 2020 Uncategorized Comments Off on $PCSA Biodegradable Implantable Sensors Can Monitor Body Functions

$NETE Mullen Technologies Positioned at the Forefront of Reduced EV Manufacturing Costs

Net Element (NASDAQ: NETE) is transforming its business model to become a pure-play electric vehicle (“EV”) manufacturer through its merger with privately-held Mullen Technologies Inc. Timing looks optimal for the transition as new research from investment bank UBS finds that the cost to manufacture EVs may be the same as the cost for regular models within the next four years (https://ibn.fm/DW8fZ). This news bodes well for Net Element and Mullen. A recent article discussing this reads, “Mullen recently announced its own plans to start work on a manufacturing facility as well as accept pre-orders for its M05 fully electric SUV. ‘We are excited to begin the build-out of our pilot facility and pre-sales of our MX-05 SUV in October,’ said Mullen Technologies chairman and CEO David Michery. ‘We plan on completing the build-out by April 2021 and to begin assembly of certification prototypes by July 2021. These vehicles will be used for homologation, which is expected to take 16 months and be completed by May of 2022, at which time we expect to begin delivering the first vehicles to the public.’”

To view the full article, visit https://ibn.fm/wIZWj

About Net Element Inc.

Net Element operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the United States and selected emerging markets. In the U.S., the company aims to grow transactional revenue by innovating SME productivity services using blockchain technology solutions and Aptito, its cloud-based, restaurant and retail point-of-sale solution. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest-growing companies in North America on Deloitte’s 2017 Technology Fast 500(TM). In 2017 Net Element was recognized by “South Florida Business Journal” as one of 2016’s fastest-growing technology companies. Further information is available at www.NetElement.com.

NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

Friday, November 13th, 2020 Uncategorized Comments Off on $NETE Mullen Technologies Positioned at the Forefront of Reduced EV Manufacturing Costs

$UUUU Investor Summit Group Releases Lineup of 77 Public Companies to Present at Virtual Fall Event

The Investor Summit Group on Thursday released further details for its Virtual Fall Summit, which is slated to take place from Nov. 16-18, 2020. The event will connect 77 presenting small and microcap companies with distinguished investors from around the globe. Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF)Sigma Labs Inc. (NASDAQ: SGLB) and Trxade Group Inc. (NASDAQ: MEDS) are among the full list of companies scheduled to present at the Fall Investor Summit. Please refer to the update for a complete list of issuers, as well as webcasting links to view the presentations.

To view the full press release, visit http://ibn.fm/Ce9NL

About Investor Summit Group

The Investor Summit Group (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. Having produced successful conferences over the past five years, the upcoming event will be the third virtual edition added to Investor Summit’s growing portfolio where hundreds of high-quality meetings between executives and investors will take place over three days. The Investor Summit Group prides itself on building community and providing a platform for the industry and looks forward to launching new features at the upcoming Fall Summit such as virtual networking, panels and a stock pitch competition to promote endless connections in a virtual format. To register for the upcoming Investor Summit, visit www.InvestorSummitGroup.com.

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Friday, November 13th, 2020 Uncategorized Comments Off on $UUUU Investor Summit Group Releases Lineup of 77 Public Companies to Present at Virtual Fall Event

$UUUU Phytomining and the Plants That ‘Bleed’ Nickel

In the heart of Sulawesi, an Indonesian island, is a small mining town by the name of Sorowako. The town is one of the biggest areas for mining nickel in the world, with one firm extracting 5% of the world’s supply of nickel from this one location.

Since 2004, Aiyen Tjoa, a lecturer and soil biologist, has been on a mission to locate rare plants that can absorb nickel from nickel-rich surroundings. The plants have the potential to absorb high amounts of the mineral from the soil and store it in high quantities. The plants could also offer an alternative nickel source, as they could be mined, offering the potential to prevent the destruction of the ecosystem caused by mineral extract.

These plants are called nickel hyper-accumulators and can hold at the minimum 1,000 mcg of nickel per 1 gram of dried leaf. The plants store the mineral in vacuoles, which is an organelle for storage in the cell. The nickel is mainly stored in their sap, roots, leaves and shoots. Some plant species such as Phyllantus balgoyii, which is found in Malaysia, have a bright blue-green colored sap as a result of extremely high nickel content. Other species such as Alyssum murale, indigenous to Italy, can absorb nearly 30,000 nickel micrograms in each gram of dried leaf.

To date, about 450 species of nickel-loving plants have been recorded globally. Many of them grow in places with lower nickel deposits and less plant diversity such as Malaysia with 24 species, New Caledonia with 65, Southern Europe with 45 and Cuba with a record 130 plant varieties. Strangely enough, Indonesia, which has the biggest nickel deposits globally and is a very biodiverse region in the world, has few of these plants.

Before Tjoa discovered two species in Sorowako in 2008, the quest had been a disappointing and painstaking research journey. She found that the indigenous plants Knema matanesis and Sacotheca celebica could amass between 1,000 to 5,000 mcg of nickel per every gram of dried leaf. However, in comparison with other nickel hyper-accumulators, the two species were at best moderate in hyperaccumulation.

Tjoa’s research is still ongoing though, as she searches for plants that could take up at least 10,000 mcg per gram. At this threshold, cultivating the plant for mineral extraction becomes economically feasible. This process is referred to as phytomining. Nickel hyperaccumulators collect nickel, which is a valuable mineral that is toxic if it remains in the soil. Nickel is used to make products such as electric car batteries and kitchen taps.

It is estimated that a nickel-loving plant such as the Phyllantus balgoyii can produce around 120 kilograms of nickel annually per hectare. Nickel extraction in this case involves the shoots being pruned (shoots have highest nickel concentrations) then burned. The nickel is then separated from the ash. The cultivation of these nickel-loving plants is carbon neutral.

As compared to traditional mining methods, phytomining has substantial environmental advantages. To extract the mineral in Sorowako, open-pit mining is used. This method produces waste materials that are toxic, and improper management of these mercury and arsenic-laden wastes may cause leaking into the surrounding environment.

Additionally, phytomining may also help rehabilitate land that’s been mined so that eventually the land can be used to cultivate normal crops. Tjoa hopes that despite the reluctance she faces now, phytomining will be adopted in the future as a safer way to mine nickel that produces less toxic waste and preserves the ecosystem.

One noteworthy company you should give some attention is Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR). From 2017 to 2019, this company stood out as the biggest U.S. producer of uranium, and it also took pole position for vanadium.

About MiningNewsWire 

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

Friday, November 13th, 2020 Uncategorized Comments Off on $UUUU Phytomining and the Plants That ‘Bleed’ Nickel

$CNSP Social Distancing Spikes Loneliness Among Older People

According to a new study by researchers from the University of Stirling, the social distancing measures introduced to help contain the coronavirus infection has affected the well-being of Scotland’s older population, increasing their feelings of loneliness.

The study discovered a connection between the worsening health and well-being of individuals over 60 years and the growth in loneliness. The research determined that increased loneliness was linked to a decrease in well-being, lower social support and a small social network.

The research was launched earlier in May under the Scottish government’s rapid research in coronavirus program. A professor of the University’s Faculty of Health Sciences and Sport, Anna Whittaker, led the study. She hopes that study findings will help in decision-making with regard to the virus and support strategies that are geared towards recovery after the pandemic.

Whittaker stated that prior studies had shown the negative effects of loneliness and social isolation. This, she said, was an important issue for older people who may not have had lots of social contact or the chance to engage with others. Whittaker added that the social-distancing guidelines that were introduced in response to the coronavirus pandemic affect vulnerable groups, such as the older people, and limit engagement in social activity.

The study surveyed 1,429 older individuals and assessed how social-distancing measures implemented during the pandemic had affected well-being, loneliness and social activity. A majority of the participants — 56% — reported that the measures made them experience less frequent social contact with fewer people, resulting in more loneliness.

The researchers discovered that better social support and a bigger social network seemed to protect against declines in well-being and health as well as an increase in loneliness. This emphasizes the importance of addressing social contact and loneliness in older individuals, especially during situations where the isolation risk is high, such as a pandemic.

Among the total number of study participants, 84% were 60 years and above and had a social network of five people on average. The participants also socialized for five days each week, for roughly six and a half hours, on average.

In addition to this, the researchers assessed the effect the measures had on physical activity. An estimated 35% of participants continued to meet their physical activity guidelines during the lockdown period with walking being the largest contributor to physical activity. Some 40% reported walking less than compared to pre-lockdown, with a similar proportion claiming that they engaged less in moderate physical activity. The researchers found that people who reported lower physical activity had poorer well-being.

CNS Pharmaceuticals Inc. NASDAQ: (CNSP) is an interesting biotech company you should watch. The company’s sole focus is to develop novel approaches in treating primary as well as metastatic forms of cancer that affect the central nervous system, and the brain.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Friday, November 13th, 2020 Uncategorized Comments Off on $CNSP Social Distancing Spikes Loneliness Among Older People

Rritual Superfoods Gains Important USDA Organic Certification for Emerging Industry Superfood Elixirs

  • Plant-based superfood developer Rritual Superfoods Inc. gained certification from the USDA validating its organic product marketing recently, helping to establish the company’s premium functional food elixirs following their launch in September
  • The initial three product line elixirs, shots and mixes promote wellness by blending select nutraceutical mushrooms with adaptogenic roots to promote the body’s immune and cognitive function, as well as to reduce stress
  • Market analysts predict the overall functional foods industry will achieve revenues of $268 billion by 2027
  • Functional mushrooms are a still-emerging subsector within the industry, allowing Rritual opportunity to build a following from the ground floor within the marketplace

Therapeutic foods innovator Rritual Superfoods is gaining attention as it helps build the emerging new market for healthful mushroom elixirs as a beneficial superfood.

On the heels of its initial product launch in September and an ECRM Buyer’s Choice Award last month for its attractive marketing and growing market presence (https://nnw.fm/FfNr8), Rritual has secured organic certification from the U.S. Department of Agriculture (“USDA”), which provides “trusted, third-party validation of the quality of Rritual’s products” beyond the unregulated claims of many products to feature “all-natural” ingredients, CEO David Kerbel noted (https://nnw.fm/6hwvE).

“We have a premium lineup that features powerful ingredients and with the addition of a Certified Organic seal our consumers can be confident they are making healthy, informed decisions about what they are putting in their body when they purchase Rritual,” Kerbel stated.

Rritual was established earlier this year, amid the outsized health concerns accompanying a worldwide pandemic, with the purpose of helping to relieve stress, heighten cognitive function and boost the immune system through healthful elixirs, shots and mixes.

The company’s initial product line features three select mushroom varieties that enjoy long-standing reputations for their beneficial biological properties. Each mushroom variety is teamed with natural “adaptogens” — herbal substances used to increase the body’s ability to resist biological stress (https://nnw.fm/ZsiCu).

“The health and wellness benefits of mushrooms and plant-based therapies are backed by decades of scientific research. Rritual’s new line of elixirs embraces that research and provides consumers with an easy way to get a daily dose of the powerful effects,” Rritual President Dr. Mike Hart stated when the product lines were announced (https://nnw.fm/OR1rX). The products will be available to consumers throughout North America during the first quarter of the new year, stepping back from the original announcement they’d be available in the fall.

The elixirs and shots will be available in 14-stick packs and in 250-gram tubs, marketed at first through Rritual’s website and the company’s Amazon store before additional retail outlets are joined through the company team’s corporate connections.

The blends include the Chaga mushroom paired with Eleuthero root to boost immunity, Lion’s Mane mushroom paired with Rhodiola root to support cognitive function and brain health, and Reishi mushroom paired with Ashwagandha root to help the body fight anxiety (https://nnw.fm/hxMnG). Each elixir also contains six other functional mushrooms as well as a prebiotic blend featuring inulin and lucuma fruit powder to support immune and digestive health.

Analysts at Research And Markets forecast the overall functional foods industry will attain revenues of $268 billion by 2027 with a growth CAGR of 6.7 percent between 2021 and 2027, demonstrating the public’s interest in consuming highly nutritious foods even when many such products are expensive and may not have rigorous testing to underly their claims (https://nnw.fm/2BILE). The emergence of the COVID-19 pandemic this year is seen as a significant driver in consumer interest toward functional foods.

For more information, visit the companys website at https://investors.WeAreRritual.com.

“Mental Fitness is a Daily Ritual”

NOTE TO INVESTORS: The latest news and updates relating to Rritual Mushrooms are available in the company’s newsroom at https://nnw.fm/Rritual

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

Friday, November 13th, 2020 Uncategorized Comments Off on Rritual Superfoods Gains Important USDA Organic Certification for Emerging Industry Superfood Elixirs

$VTGN Reports Positive Preclinical Data on PH94B’s Mechanism of Action

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced new in vitro electrophysiology data. According to the update, the data demonstrate that the mechanism of action of PH94B, the intranasal neuroactive steroid the company is preparing for Phase 3 development as a potential acute rapid-onset treatment of anxiety in adults with social anxiety disorder, does not involve direct activation of GABA-A receptors, in distinct contrast to the mechanism of action of benzodiazepines (“benzos”), which act as direct positive modulators of GABA-A receptors. “We are very pleased with the results of these studies that suggest PH94B’s mechanism of action may not have benzodiazepine-like side effects, such as sedation and cognitive impairment, or abuse liability,” stated VistaGen CEO Shawn K. Singh. “While benzodiazepines provide relief for many Americans struggling with anxiety, their extremely risky safety profile does not lend itself to long term use. The mechanism of action contributes to the safety profile. As we have seen in Phase 2 clinical studies, while PH94B is able to produce rapid-onset benzo-like, anti-anxiety effects, this study demonstrates that PH94B does not have a benzo-like mechanism of action. As we approach Phase 3 development of PH94B, especially given the FDA’s recent public announcement about safety concerns associated with benzo use, these new data make us even more excited about PH94B’s potential to change lives without the risky side effects and safety concerns of benzos.”

To view the full press release, visit: https://ibn.fm/mNCyV

About VistaGen Therapeutics

VistaGen is a clinical-stage biopharmaceutical company developing and commercializing differentiated new generation medicines that go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on TwitterLinkedIn and Facebook.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at http://ibn.fm/VTGN

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Thursday, November 12th, 2020 Uncategorized Comments Off on $VTGN Reports Positive Preclinical Data on PH94B’s Mechanism of Action

$VTGN CEO Discusses ‘Game-Changing’ Potential of Drug Pipeline Lineup in Stock2Me Podcast

  • VTGN is committed to developing and commercializing differentiated new generation medications that go beyond the current standard of care for anxiety, depression and other CNS disorders.
  • VTGN currently has three drugs in its pipeline, PH94B and PH10, both innovative synthetic neuroactive steroid nasal sprays, and AV-101, a novel, oral prodrug that targets the NMDAR.
  • VTGN has opportunity, based on current drug-development programs, to “shift the paradigm.”

VistaGen Therapeutics (NASDAQ: VTGN) CEO Shawn Singh spoke about VistaGen’s game-changing potential for the treatment of mental illness during a recent episode of InvestorBrandNetwork’s Stock2Me Podcast (https://ibn.fm/34My5). A clinical-stage biopharmaceutical company, VTGN has three drugs in its pipeline and is committed to developing and commercializing new generation medications that go beyond the standard of care for anxiety, depression and other central nervous system (“CNS”) disorders.

During the podcast, Mr. Singh spoke about his motivation to bring much needed innovation to the current treatment paradigm for anxiety and depression disorders, noting, “VistaGen provides, I think, an opportunity for tremendous excitement, given what we’re working on in our pipeline. We have three drug candidates focused on trying to go beyond the current standard of care for anxiety, depression and other CNS, or central nervous system, disorders.”

VistaGen’s three pipeline drugs include the following:

  • PH94B, an innovative synthetic neuroactive steroid nasal spray with therapeutic potential in a wide range of mental health disorders involving anxiety or phobia, currently being developed as a potential acute treatment of anxiety for adults with Social Anxiety Disorder (“SAD”).
  • PH10, an innovative synthetic neuroactive steroid delivered intranasally with therapeutic potential in a wide range of neuropsychiatric indications involving depression and initially being developed as a potential rapid-onset stand-alone treatment of major depressive disorder (“MDD”).

AV-101, an oral prodrug that targets the glycine site of the NMDAR (N-methyl-D-aspartate receptor), an ionotropic glutamate receptor in the brain, has potential to be an oral, new generation treatment for multiple CNS indications involving abnormal NMDAR function.

“What’s exciting about all of these [drug candidates] and where we see some game-changing potential in the landscape is the way they work and how fundamentally different we think each of them is from current treatment alternatives,” Singh said. “The way a drug works and the way it works in the brain for a neuropsychiatric indication is critical.

“We’ve got an opportunity, based on the drug-development programs we’ve got moving, to really swing the paradigm into a different direction where patients can learn faster whether a drug is going to deliver a benefit, and they’re not going to have to, during that period, worry as much about the types of side effects and safety concerns that are associated with current therapies,” he continued.

Click here to listen to the entire podcast.

VistaGen is a clinical-stage biopharmaceutical company committed to developing and commercializing differentiated new generation medications that go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders. Each of VistaGen’s three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential in multiple CNS markets.

For more information, visit the company’s website at www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Thursday, November 12th, 2020 Uncategorized Comments Off on $VTGN CEO Discusses ‘Game-Changing’ Potential of Drug Pipeline Lineup in Stock2Me Podcast

$WTER 420 with CNW – Connecticut Governor Says Legalizing Pot Good for Public Health Amid Pandemic

With several states legalizing cannabis use, marijuana tourism has been on the rise. Cannabis tourism, or traveling across state lines to purchase and consume the infamous plant, attracts millions of visitors and dollars to states that allow recreational cannabis. However, with the coronavirus pandemic raging, traveling across state lines for cannabis may not be safe, says Connecticut Gov. Ned Lamont.

In an interview with Yahoo Finance, Gov. Lamont said that legalizing cannabis amid the coronavirus crisis would be a big win for public health. With work-from-home and social-distancing measures in place to curb the spread of the virus, the last thing states need is people driving back and forth across state lines for marijuana. Connecticut doesn’t allow recreational cannabis yet but is surrounded by states that do, creating a situation where consumers are more likely to travel to neighboring states.

During his interview, Lamont stated that officials have “got to think regionally when it comes to how we deal with the pandemic, and I think we have to think regionally when it comes to marijuana as well.” When asked whether he would pursue cannabis legalization next year, Lamont said that he thinks he will.

Connecticut is facing a budget deficit of $2 billion, and the governor has shied away from increasing taxes or cutting government spending. Without stimulus funds, he says, Connecticut may very well slide into a mild recession and suffer even more job losses. The cannabis industry has proven to be quite resilient during the pandemic, and taxing cannabis sales would be a great way to close the deficit and boost revenues.

“Right now, I’m surrounded by states — New Jersey and Massachusetts — where marijuana is already legal,” said Lamont. “I don’t need a lot of people driving back and forth across the border. We’re trying to keep people close to home as best as we can right now. I think legalizing marijuana, doing that safely and making sure no poison is laced in, I think is one way to keep people closer to home.”

Although voters in neighboring New Jersey voted in favor of a referendum to legalize cannabis during last week’s election, marijuana possession, use and sales will still be prohibited until lawmakers pass enabling legislation for the program. In a separate appearance, Lamont stated that the passage of cannabis legislation in New Jersey as well as ongoing cannabis reform efforts throughout the Northeast underscores the need for Connecticut to enact cannabis policy change.

A company you should watch in the marijuana industry is The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER). This maker of alkaline as well as flavored water has also unveiled a line of CBD-infused products.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Thursday, November 12th, 2020 Uncategorized Comments Off on $WTER 420 with CNW – Connecticut Governor Says Legalizing Pot Good for Public Health Amid Pandemic

$SGTM Announces Expansion of Mulch Contract with Circle K Convenient Stores

Sustainable Green Team (OTC: SGTM), a leading provider of environmentally beneficial solutions for tree and storm waste disposal, today announced that its wholly owned subsidiary Mulch Manufacturing Inc. has expanded its 2021 mulch contracts with Circle K convenient stores, a subsidiary of Alimentation Couche-Tard Inc. (OTC: ANCUF) (“ANCUF”). According to the update, the original contract finalized in October was increased to add an additional region to the initial three, bringing the total to four. SGTM obtained the mulch contract expansion shortly after reporting another successful quarter in which it generated approximately $24.5 million in revenue and $5.5 million in gross profit within the nine months ending Sept. 30, 2020.

To view the full press release, visit https://ibn.fm/QrfTn

About Sustainable Green Team Ltd.

Sustainable Green Team, through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation. The company’s solutions are founded in sustainability, based on vertically integrated operations that begin with collecting of tree debris through its tree services division and collection sites, then, through its processing division, recycling and using that tree debris as a feedstock that is manufactured into a variety of organic, attractive, next-generation mulch products that are packaged and sold to landscapers, installers and garden centers. The company plans to expand its operations through a combination of organic growth and strategic acquisitions that are both accretive to earnings and positioned for rapid growth from the resulting synergistic opportunities identified. The company’s customers include governmental, residential, and commercial clients. For information regarding SGTM’s operations, expansion plans and production facilities, visit http://ibn.fm/NYk36

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Thursday, November 12th, 2020 Uncategorized Comments Off on $SGTM Announces Expansion of Mulch Contract with Circle K Convenient Stores

$PCSA Announces Third Quarter 2020 Results, Provides Corporate Update

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) (“Processa” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of drug products that are intended to provide treatment for and improve the survival and/or quality of life for patients who have unmet medical needs or conditions or who have no alternative treatment, today reports financial results for the third quarter of 2020.

Dr. David Young, CEO and chairman of Processa, commented, “The third quarter was a period of tremendous value creation. Over that time, we in-licensed important clinical drug candidates PCS12852 and PCS6422, uplisted to Nasdaq and closed a $19.2 million public offering. Due to those achievements, we now have sufficient funds to complete three trials for three distinct markets, each exceeding $1 billion. Importantly, we are developing products for which existing clinical evidence of efficacy has already been established. With key milestones to announce over the next 12-18 months, including interim data for PCS6422 in 3Q21 and PCS499 in 4Q21, we are excited about the near-term opportunity of increasing shareholder value.”

Recent Highlights and New Developments

  • Entered into an exclusive licensing agreement with Elion Oncology, Inc. to develop, manufacture and commercialize eniluracil (PCS6422) globally. PCS6422 is an oral drug to be administered with fluoropyrimidine cancer drugs (e.g., capecitabine, 5-FU). PCS6422 is designed to decrease the breakdown of the cancer drugs, which, without such intervention, reduce to inactive metabolites or metabolites that are known to cause unwanted side effects and to interfere with the anticancer activity.
  • Entered into a licensing agreement with Yuhan Corporation, a publicly traded South Korean company, to license PCS12852, a small molecule drug in development for the treatment of functional gastrointestinal (GI) disorders (FGID).
  • Appointed Dr. Khalid Islam to the Company’s board of directors.
  • Appointed Michael Floyd as the Company’s chief operating officer.
  • Uplisted to Nasdaq.
  • Closed an underwritten public offering of 4,800,000 shares of common stock for a price to the public of $4.00 per share. Net proceeds to the Company were approximately $17.1 million.

Upcoming Clinical Drug Development Milestones

1H 2021

  • Phase 1B First Patient Dosed: PCS6422 (Cancer)
  • Phase 2B First Patient Dosed: PCS499 (Ulcerative NL)
  • FDA IND Submission: PCS12852 (GI/Gastroparesis)

2H 2021

•     Interim Cohort Results Begin: PCS6422

•     Interim Results: PCS499

•     Phase 2A First Patient Dosed: PCS12852

Financial Results for the Third Quarter Ended Sept. 30, 2020

General and administrative expenses were approximately $423 thousand for the quarter ended Sept. 30, 2020, compared to approximately $419 thousand during the third quarter ended Sept. 30, 2019.

Research and development expense totaled approximately $533 thousand for the third quarter ended Sept. 30, 2020, compared to approximately $585 thousand during the third quarter ended Sept. 30, 2019.

Net loss attributable to common stockholders for the third quarter ended Sept. 30, 2020 was $3.1 million, compared to $864 thousand for the third quarter ended Sept. 30, 2019.

As of Sept. 30, 2020, the Company had cash and cash equivalents of approximately $325 thousand. Subsequent to the quarter end, Processa closed a $19.2 million gross proceeds public offering of common stock resulting in net proceeds of approximately $17.1 million after deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Following the close of the offering and related transactions the Company will have 13.8 million common shares outstanding.

Conference Call Information

To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.

Date: Nov. 12, 2020
Time: 5:30 p.m. ET
Dial-In Information: Toll Free: 877-876-9176
International: 785-424-1670

Live Webcast: https://www.webcaster4.com/Webcast/Page/2572/38528

Conference Call Replay Information

Toll-free: 877-481-4010
International: 919-882-2331
Replay Passcode: 38528

Replay Webcast: https://www.webcaster4.com/Webcast/Page/2572/38528

About Processa Pharmaceuticals, Inc.

The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The Company used these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com .

Forward-Looking Statements

This release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements that involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Please refer to the documents filed by Processa Pharmaceuticals with the SEC, specifically the most recent reports on Forms 10-K and 10-Q, which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements.

For More Information:
Michael Floyd
(301) 651-4256
mfloyd@processapharma.com

James Carbonara
Hayden IR
(646) 755-7412
james@haydenir.com

Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

Thursday, November 12th, 2020 Uncategorized Comments Off on $PCSA Announces Third Quarter 2020 Results, Provides Corporate Update

$POAI Poised at Convergence of AI, Cancer Care

Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company, focuses on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. The company is set to play a key role as the integration of AI technology within cancer care continues to improve the accuracy and speed of diagnosis, aid in clinical decision-making and lead to better health outcomes. A recent article discussing growing opportunity in this sector reads, “The National Cancer Institute (‘NCI’) in the United States has separately revealed that it is increasingly looking to invest in supporting research and developing infrastructure centered around the usage of AI in developing oncological treatments (https://ibn.fm/BFD5m). This is a niche where Predictive Oncology is increasingly building a dominant presence. In addition, the White House has announced $2 billion funding for public and private sector ‘AI hubs’ designed to drive key advances in AI as well as other computational technologies (https://ibn.fm/kcgSH).”

To view the full article, visit: https://ibn.fm/582At

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions by providing an evidence-based road map for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Thursday, November 12th, 2020 Uncategorized Comments Off on $POAI Poised at Convergence of AI, Cancer Care

$POAI Research Discovers That Suicide Rates Spike After Disasters Occur

A group of researchers from the University of Delaware have examined how suicide rates are influenced by various natural disasters. Natural disasters may include tornadoes, floods and hurricanes. and as climate change becomes more harmful, we are seeing these disasters occurring more frequently, each more serious than the last. In fact, the group measured 281 disasters over a 12-year period.

Factoring in the effect natural disasters have on local communities, their economies and their infrastructure, it might be plausible to argue that disasters can also cause severe anxiety and emotional distress. The founding director of the University of Delaware’s College of Health Sciences’ epidemiology program, Jennifer Horney was among the scientists who conducted this research.

The researchers observed disaster declaration data and discovered that, when compared to suicide rates before and after a disaster occurred, overall suicide rates grew by 23%. The article, which was published in the “Journal of Crisis Intervention and Suicide Prevention,” states that the suicide rates grew for all disasters including ice storms, hurricanes, floods and severe storms.

Horney explains that the research findings are important as those deaths could be prevented if disaster preparedness and response was better. In addition, people should be aware that the risk of suicide is increased in individuals with more social vulnerabilities who live in areas with a higher risk of destruction by disasters.

The researchers observed counties in the United States with one major disaster declaration in the 2003–2015 period. This designation was based on data from the Federal Emergency Management Agency (FEMA). Suicide rates were estimated based on three, twelve-month periods before and after a disaster occurred for each county. Even though only nine types of disasters are given as disaster declarations by FEMA, hurricanes, floods and storms were included in the study because they occurred frequently.

Researchers discovered that for all types of disasters combined and also individually for ice and severe storms as well as flooding, rates of suicide grew in the first and second years after a disaster hit then decreased in the third year. After a hurricane hit, however, suicide rates increased in the first year by roughly 26% before they dropped to the baseline rate in the second year. Flooding increased suicide rates by almost 18% and in the second year by 61% before decreasing to the baseline rate later.

Horney stated that the counties most affected by hurricanes recorded the largest growths in suicide rates in the first year. This, she says, makes sense as they were the most common disaster areas assessed in the study. Horney added that more mental health resources addressing issues arising from natural disasters needed to be made available, and the research findings only add on to this.

Predictive Oncology (NASDAQ: POAI) is a firm you should watch in the biomedical sector. It specializes in using analytics as well as artificial intelligence to develop personalized remedies to different kinds of cancer.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Thursday, November 12th, 2020 Uncategorized Comments Off on $POAI Research Discovers That Suicide Rates Spike After Disasters Occur

$NETE Motorcycle Manufacturers Unveils Low-Cost Electric Scooter for Urban Use

Not many people think of scooters and motorcycles when the subject of electric vehicles (“EVs”) comes up, but these two-wheeled mobility tools have witnessed a transformation as manufacturers venture into the EV space. Yamaha (OTC: YAMHF) is one of those manufacturers that now offers electric motorcycles as well as electric scooters.

The Japanese manufacturer’s newest offering is a scooter that looks similar to the Vesper. Named e-Vino, the scooter is intended for urban use because of its small size as well as its limited range.

The pint-sized scooter weighs only 149.9 pounds. This weight bumps up to 163 pounds when one battery back is installed. The battery pack is itself of a low capacity, standing at 500 Wh. It is expected that most owners of the e-Vino will likely exercise the option of installing a second battery since the scooter can only cover a total of 18 miles on a single battery charge. A second battery would double that range to 36 miles.

It is interesting to note that the range above was calculated based on a rider moving at a rather modest speed of 18 mph; the rider envisaged during the range test weighed in at just 121 pounds. Real-life scenarios regarding both the weight of riders and the speed at which they’d likely move around urban centers would likely differ greatly from those test parameters, so many scooter owners may be disappointed by the performance of the e-Vino.

To be fair to the scooter, you don’t need a lot of range if you only move around the city. Additionally, the e-Vino’s small battery pack can be recharged in only three hours, so that gives a rider plenty of time to juice up while at work or attending classes. Another plus of these small battery packs is that a rider can remove the battery from the scooter to charge them, perhaps in an office or visiting friends, etc.

In addition, the e-Vino has a less-than-impressive motor, coming in at a modest 580w or a peak power of 1,200w when the Boost button is pressed. This button briefly bumps up the power of the scooter, a feature that could come in handy when climbing a hill, for example.

Speed is certainly not going to be a deciding factor should another e-Vino rider challenge you to a race. Rather, the winner is likely to be the rider who weighs less since such a rider may squeeze as close to the scooter’s top speed of 27 mph as possible.

Nevertheless, for anyone who wants to move from point A to B within city limits, Yamaha’s e-Vino can be counted on to do just that. And the bonus? The scooter costs just $2,280.

Net Element (NASDAQ: NETE) is one you should watch in the electric vehicle space. This financial services company announced months ago that it was merging with Mullen Technologies Inc., a California-based manufacturer of lightweight commercial electric vehicles.

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com

Green Car Stocks is part of the InvestorBrandNetwork.

Thursday, November 12th, 2020 Uncategorized Comments Off on $NETE Motorcycle Manufacturers Unveils Low-Cost Electric Scooter for Urban Use

$ICLK Announces Its Addition to MSCI China Small Cap Index

iClick Interactive (NASDAQ: ICLK), an independent online marketing and enterprise data solutions provider in China, has announced that its stock will be added to the MSCI China Small Cap Index. That addition is scheduled to take place at market close on Nov. 30 , 2020. The MSCI China Small Cap Index is compiled by MSCI Inc., a leading provider of research-based indexes and analytics. With 232 constituents, the index represents approximately 14% of the free float-adjusted market capitalization of the China equity universe. Designed to track and gauge the performance of China’s small cap market, the index is broadly recognized as a benchmark for global institutional investors to optimize their investment portfolios.

To view the full press release, visit http://ibn.fm/OFHeO

About iClick Interactive Asia Group Limited

iClick Interactive is an independent online marketing and enterprise data solutions provider that connects worldwide marketers with audiences in China. Built on cutting-edge technologies, the company’s proprietary platform possesses omni-channel marketing capabilities and fulfils various marketing objectives in a data-driven and automated manner, helping both international and domestic marketers reach their target audiences in China. Headquartered in Hong Kong, iClick was established in 2009 and is currently operating in 10 locations worldwide including Asia and Europe. For more information about the company, please visit www.iClick.com.

NOTE TO INVESTORS: The latest news and updates relating to ICLK are available in the company’s newsroom at http://ibn.fm/ICLK

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com

InvestorWire is part of the InvestorBrandNetwork.

Thursday, November 12th, 2020 Uncategorized Comments Off on $ICLK Announces Its Addition to MSCI China Small Cap Index

$UUUU to Present at Virtual Fall Investor Summit

Energy Fuels (NYSE American: UUUU) (TSX: EFR), the current leading U.S. producer of uranium, the top U.S. producer of vanadium in 2019, and focused on the potential to begin producing a rare earth element (“REE”) concentrate at its White Mesa Mill, will be presenting at this year’s virtual Fall Investor Summit. The event is slated to take place from Nov. 16-18 in a virtual format and feature 75 companies and over 300 institutional and retail investors. Interested parties should visit https://ibn.fm/fpEn2 for more details and to register for the Fall Investor Summit.

To view the full press release, visit https://ibn.fm/A4Lxs

About Energy Fuels Inc.

Energy Fuels is the number one U.S. producer of uranium. The company was also the top U.S. producer of vanadium in 2019 and is conducting pilot-scale testing to potentially begin producing a rare earth element (“REE”) concentrate at its White Mesa Mill. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, it is licensed to produce over 8 million pounds of U3O8 per year, and it has the ability to produce vanadium and a rare earth element concentrate. The Nichols Ranch ISR Project is fully licensed, constructed and on standby, and licensed to produce 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also fully licensed, constructed and on standby, and licensed to produce 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has the largest NI 43-101 compliant uranium resource portfolio in the U.S., among producers, and several uranium and vanadium mining projects on standby and in various stages of permitting and development. Energy Fuels’ corporate offices are in Lakewood, Colorado near Denver. For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

About MiningNewsWire

MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.

To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.MiningNewsWire.com

Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer

MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com

MiningNewsWire is part of the InvestorBrandNetwork.

Thursday, November 12th, 2020 Uncategorized Comments Off on $UUUU to Present at Virtual Fall Investor Summit

$DRIO Releases Financial Results for Third Quarter

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has released its financial results for Q3 2020. In addition, the company reported on important third-quarter highlights and provided an update on key objectives. Dario ended the third quarter with cash and cash equivalents of $37 million and plans to focus on its U.S. commercial sales and marketing infrastructure with the end goal of B2B2C pipeline growth. In addition, through its agreements with Vitality Group and HMC Healthworks, the company is committed to becoming a B2B2C digital therapeutics leader. The report also noted that Eric Milledge had been appointed chairman of the company’s recently announced Scientific Advisory Board. “During the third quarter we achieved 14.2% sequential growth in our revenues, but more importantly, we made significant strides in penetrating the multiple verticals within the Business-to-Business-to-Consumer (B2B2C) channel with our digital therapeutics solutions,” said Dario CEO Erez Raphael in the press release. “Most notably, our recently announced partnership agreements with Vitality Group and HMC Healthworks provide access of our solutions to end users through their employers or benefits providers. . . The execution of our multi-year, strategic plan has led to advanced late-stage contracting discussions with health plans, self-insured employers and providers. We are encouraged by the fact that we are pursuing multiple large opportunities, and we anticipate many of these agreements will close and launch in the near term. Furthermore, as our sales pipeline has grown during the third quarter, we believe that our ongoing investments in our U.S. commercial infrastructure have positioned Dario for a transformational year in 2021.”

To view the full press release, visit: https://ibn.fm/41TPS

About DarioHealth Corp.

DarioHealth Corp. is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, the company empowers individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Dario’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. For more information about the company, please visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Thursday, November 12th, 2020 Uncategorized Comments Off on $DRIO Releases Financial Results for Third Quarter

$DRIO Researchers Uncover Two Factors That Turn Cells Cancerous

In a novel study that was published in “Cell Metabolism,” researchers have discovered two pathways that may connect more than 100 types of cancer. For a long time, scientists believed that all cancers were controlled by the same set of basic processes. The researchers, who are from the University of Pennsylvania Perelman School of Medicine, may have identified a combined process that could be used to develop new therapies that would prevent cells from mutating into any type of tumor, whether it is colon, prostate or breast tumor.

The team of researchers discovered that the enhancement of two elements (nucleotide synthesis and antioxidant defense) transformed a cell into a cancerous cell. Cancer genes were found to be influencing some cells to synthesize nucleotides and repel oxidative stress, which the cells require to grow and survive.

A professor of cancer biology and the senior author of the study Xiaolu Yang stated that from the 1980s, many cancer genes have been identified, but when they affect various cellular processes, it gets harder to pinpoint exactly what makes the cells cancerous. The study looked into how a specific metabolic enzyme influence changes in a cell; the study found that to make a cancer cell from a phenotypically normal one, the normal cell had to be supplied with extra capacity to generate nucleotides and bear oxidative stress. However, if these metabolic pathways were collapsed, the cells wouldn’t become cancerous.

The researchers produced the G6PD gene in abnormally large amounts. This gene is responsible for making the glucose-6-phosphate dehydrogenase in human and mice cells. This enzyme is involved in the processing of carbohydrates and is active in almost all the cells in the body. The researchers demonstrated that this overproduction of the G6PD gene alone brought about tumors in mice and caused cells in humans to become cancerous. The group members also discovered that the G6PD gene encouraged the generation of a co-enzyme that prevents cells from being damaged and killed.

Research results also show that antioxidants do not reduce tumor growth; rather, they but support it. A tumor requires a strong antioxidant defense to develop, so by providing more antioxidants, the body creates an ideal environment for tumors to grow.

The authors state that the study also shows a molecular framework that will help scientists understand the oncogenesis process better and also develop new approaches to treat cancers. Yang adds that the combination of therapeutics that impact the two events mentioned above would be successful in preventing normal cells from becoming cancerous.

An entity you need to pay attention to within the biotech field is DarioHealth Corp. (NASDAQ: DRIO). This company focuses on delivering digital therapeutic solutions that help people with chronic diseases to easily implement the lifestyle changes they need to manage their conditions.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Thursday, November 12th, 2020 Uncategorized Comments Off on $DRIO Researchers Uncover Two Factors That Turn Cells Cancerous

$CNSP Hosting Webcast for Discussion of Phase 2 Clinical Trial Design

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has scheduled a webcast today during which it will be discussing its plan to submit a phase 2 clinical trial design for FDA review. The call, which will be moderated by Robert LeBoyer, managing director of Equity Research at Ladenburg Thalmann & Co. Inc., will start at 4:30 p.m. ET. The phase 2 trial design is for the U.S. trial for CNSP’s Berubicin. Berubicin is the company’s lead drug candidate for the treatment of glioblastoma multiforme (“GBM”). The phase 2 trial is comprised of randomized patients who will receive either Berubicin or standard of care. Interim assessments will be conducted to evaluate the comparative safety and effectiveness of these treatments. CNS Pharmaceuticals anticipates submitting an Investigational New Drug (“IND”) application to the U.S. Food & Drug Administration (“FDA”). That application will include a novel clinical trial designed to build on the results reported from the drug’s phase 1 clinical trial.

To view the webcast, visit https://ibn.fm/dx6VN

To view the full press release, visit: https://ibn.fm/xUIus

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the United States, while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. The company’s second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information about the company, please visit www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Thursday, November 12th, 2020 Uncategorized Comments Off on $CNSP Hosting Webcast for Discussion of Phase 2 Clinical Trial Design

$CYBN.NE Savvy Companies Making Moves in Drug-Development Space

NetworkNewsWire Editorial Coverage: Drug development means big money these days as big pharma and life science companies work to discover treatments that make a difference in the world. Investors are showing strong interest in the drug-development industry, and savvy companies are also making strategic M&A moves to strengthen their positions in the growing space. Life sciences company Cybin Inc. (NEO: CYBN) (Cybin Profile) exemplifies what is happening. The company, which focuses on developing psychedelic therapeutics along with unique delivery mechanisms that target depression as well as other psychiatric and neurological condition, just completed a reverse takeover. Other announcements in the drug-development space also shine a spotlight on the action taking place in this dynamic sector. Johnson & Johnson (NYSE: JNJ) just completed the acquisition of Momenta Pharmaceuticals Inc. H. Lundbeck AS ADR (OTC: HLUYY) finalized its acquisition of Alder BioPharmaceuticals, a company committed to transforming migraine treatment and prevention. Karuna Therapeutics Inc. (NASDAQ: KRTX) executed an underwritten public offering of 2,600,000 shares of its common stock, and Sage Therapeutics Inc. (NASDAQ: SAGE) hosted an exclusive event to discuss its research and development strategy as well as provide clinical progress in its key programs.

  • Company’s reverse takeover forms publicly traded company focused on psychedelic therapeutics.
  • Groundbreaking research reports that psilocybin treatment had “more than four times greater effect” than typical antidepressant medications.
  • Multiple studies and trials create strong Cybin pipeline.

An Innovative Public Company

Significant amounts of money are being invested in the drug-development sector, and Cybin Inc. (NEO: CYBN) could see significant benefits. The leading life sciences company recently completed a reverse takeover, and just this month, Cybin start trading common shares on the NEO exchange under the symbol CYBN.

Cybin management notes that the reverse takeover of Clarmin Explorations Inc. will result in an innovative public company focused on psychedelic drug development, unique delivery mechanisms, and improved novel compounds and protocols that could offer relief to the millions that suffer from depression and other psychiatric or neurological conditions.

“We are very pleased to have completed the Reverse Takeover and to have received conditional approval to list CYBIN’s shares on the NEO Exchange,” said Cybin CEO Doug Drysdale. “We anticipate it will help us to enhance our visibility within the investment community and broaden our investor base, with the goal of building long-term shareholder value. It also represents an important step forward in advancing our development plans. We believe in the application of psychedelic therapies and look forward to advancing them and our other product candidates.”

Previously Cybin announced the closing of a private placement offering resulting in aggregate gross proceeds of CDN$45 million. The company intends to use the net proceeds from this offering to develop the company’s psychedelic therapies and nutraceutical products, as well as for working capital and general corporate purposes. The offering included participation from several new investors including RA Capital Management, Janus Henderson Investors, Kearny Venture Partners, LifeSci Venture Partners and Bail Capital.

An Enormous Unmet Need

Depression is often a little-discussed secret, but it is estimated that more than 17 million adults in the United States alone experienced at least one major depressive episode last year, and  one out of every four people struggle with a diagnosable mental disorder. The need for treatment options is clear. Cybin is committed to finding answers to address this enormous unmet medical need. The company is working to become the first life sciences company to bring an effective psilocybin therapeutic drug to market targeting major depressive disorder (MDD).

Earlier this month, an article in the journal JAMA Psychiatry reported the remarkable findings of a study featuring the hallucinogen psilocybin, which appears to support Cybin’s efforts. During the study, 27 patients received two doses of psilocybin on different days and also received more than 10 hours of psychotherapy. The group was divided into two groups, with one group receiving treatment immediately while the second group waited for a period of time. The research team reported that the psilocybin treatment had an effect “more than four times greater” than the typical antidepressant medications.

In an NPR article titled “Rigorous Study Backs a Psychedelic Treatment for Major Depression,” Alan Davis, an author of the study and a faculty member at both Johns Hopkins University and Ohio State University, noted that “there was a significant reduction in depression in the immediate-treatment group compared to those in the waitlist. . . The effect happened within one day after the first session and sustained at that reduced level through the second psilocybin session all the way up to the one-month follow-up.”

“The study is notable for its scientific rigor,” said Charles F. Reynolds III, MD, distinguished professor emeritus of psychiatry at the University of Pittsburgh’s School of Medicine. “It offers, I think, a good deal of promise as a feasible approach to treating particularly chronic forms of depression.” Reynolds also observed that the emergence of treatments such as psilocybin may signal a new era in treatments.

Game-Changing Advancements

In the JAMA article, the author stated the need for additional research and study on all aspects psilocybin in order to confirm the results. Those efforts are well underway at Cybin. The company has already entered into a feasibility agreement with IntelGenx Corp. for the development of a sublingual film for the delivery of pharmaceutical-grade psilocybin. The results of partnership could lead to game-changing advancement not only for the delivery  of psilocybin therapeutics but also for treatments of other types mental disorders.

“Compared to oral psilocybin capsules, which are subject to variable intestinal absorption and high first-pass metabolism in the liver, the systemic bioavailability of [sublingual] psilocybin film is expected to be quite high,” said Cybin chief medical officer, Jukka Karjalainen MD. “Additionally, the dose of psilocybin administered by a [sublingual] film is expected to be a fraction of the requirement in oral capsules. These features have the potential to increase both the safety and efficacy of psilocybin when administered in this manner.”

The agreement with IntelGenx is one of the several clinical trials and studies in the company’s rapidly growing pipeline. Other trials and studies include the following:

  • A phase 2a and phase 2b clinical trial to fast track drug approval targeting Major Depressive Disorder (MDD).
  • A clinical safety and efficacy study targeting microdosing that may lead to a clinical trial for anxiety, ADHD and overall cognitive flexibility
  • A phase 2 clinical trial targeting addition through the delivery of psilocybin through a sublingual film, with further studies leveraging a transdermal, “slow-dose” delivery mechanism.

An innovator with expertise in one of the most promising options for mental disorders, Cybin appears to be moving forward quickly in the research and development space.

The Pursuit of Treatments

Other companies are joining Cybin in the pursuit of more effective treatments to provide help to those suffering from all types of illnesses and disorders. In doing so, these companies are making strategic moves to increase their funding and strengthen their portfolios.

Johnson & Johnson’s (NYSE: JNJ) acquisition of Momenta Pharmaceuticals Incbroadens the leadership of Janssen Pharmaceutical Companies in the autoimmune diseases space. The move also provides a major catalyst for sustained growth. “We’re delighted to welcome Momenta’s talented team to the Janssen Pharmaceutical Companies of Johnson & Johnson and to begin our work together to further advance patient care in autoantibody-driven diseases,” said Jennifer Taubert, executive vice president and worldwide chairman of pharmaceuticals for Johnson & Johnson. “We anticipate multiple launches, many of which would be first-in-class indications in rare diseases and areas of significant unmet need.”

In a move designed to enhance its brain-disease therapy options, H. Lundbeck AS ADR (OTC: HLUYY) acquired Alder BioPharmaceuticals. Alder brings eptinezumab to the table. Eptinezumab is an investigational monoclonal antibody (mAb) that is administered as a quarterly 30-minute IV infusion. The transaction should significantly accelerate and strengthen the build of Lundbeck’s pipeline. Alder submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for eptinezumab last year, and the FDA approved Vyepti(TM) (eptinezumab-jjmr) as the first and only intravenous preventive treatment for migraine in February of this year.

A clinical-stage biopharmaceutical company, Karuna Therapeutics Inc. (NASDAQ: KRTX) late last year announced a public offering of common stock. Karuna is committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain. The company is working to deliver more effective and better-tolerated treatments for large and underserved patient populations. Its lead product candidate, KarXT, is under development as an investigational treatment for schizophrenia and dementia-related psychosis.

Sage Therapeutics Inc. (NASDAQ: SAGE) provided an innovative look at its research and development strategy during its September 2020 “FutureCast: An R&D Portfolio Review.” The program also provided an overview the company’s  progress in its key depression, neurology, and neuropsychiatry franchise programs. “The team at Sage continues to follow the science with a fundamentally different approach, using our strong medicinal chemistry and focus on translational data to efficiently approach drug development,” said Sage CEO Jeff Jonas, MD. “We continue to focus on areas where our early clinical data suggest the potential for meaningful patient benefit, not just incremental change.”

A focus on drug development and meeting the needs of an underserved and suffering population looks to be a promising place to be.

For more information about Cybin, please visit Cybin Inc.

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 40+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

Thursday, November 12th, 2020 Uncategorized Comments Off on $CYBN.NE Savvy Companies Making Moves in Drug-Development Space

Rritual Receives USDA Organic Certification, Official Confirmation of Product Quality

Rritual announced that it has received the United States Department of Agriculture (“USDA”) Organic Certification. Awarded only after a demanding vetting process, the seal confirms the high quality of Rritual’s product lineup and manufacturing process. Rritual launched its original product lineup in September, which features products formulated with mindfully selected functional mushrooms and adaptogenic herbs. The products are designed to help relieve stress, improve cognitive function and support the immune system. As a Certified Organic company, Rritual meets a strict process that verifies its ingredients are free from antibiotics, toxic pesticides, synthetic hormones and genetically modified organisms (“GMOs”). In addition, Rritual products must contain 95% or more organic ingredients and have been produced according to the USDA standards and regulations. “Receiving USDA Organic Certification provides trusted, third-party validation of the quality of Rritual’s products,” said Rritual CEO David Kerbel in the press release. “We have a premium lineup that features powerful ingredients and with the addition of a Certified Organic seal our consumers can be confident they are making healthy, informed decisions about what they are putting in their body when they purchase Rritual.”

To view the full press release, visit https://ibn.fm/Ai1ED

About Rritual

Launched in 2020, Rritual is guided by a single purpose: to help everyone meet the demands of modern life with style and ease through mushroom adaptogens. Rritual makes premium plant-based elixir products in small batches featuring mindfully selected functional mushrooms and adaptogenic herbs. To help support and achieve an optimal need-state, Rritual offers a range of products to fit every lifestyle. Rritual produces simple mushroom adaptogen products with limited yet very purposeful and organic ingredients. Most of all, Rritual wants to help people adapt to the strain of modern life and prove that mushrooms and many adaptogenic herbs truly are the world’s greatest superfoods. To learn more about the company, please visit www.WeAreRritual.com.

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Thursday, November 12th, 2020 Uncategorized Comments Off on Rritual Receives USDA Organic Certification, Official Confirmation of Product Quality

$PULL Announces Board Appointment of Dwight Duncan

Pure Extracts Technologies (CSE: PULL), a plant-based extraction company focused on cannabis, hemp, and functional mushroom sectors, on Tuesday announced the appointment of Dwight Duncan to its board of directors. Duncan serves as a senior strategic advisor at McMillan LLP, a large Canadian full-service business law firm. He also serves as a principal of McMillan Vantage, McMillan LLP’s wholly owned public policy advisory firm, and chairs the board of directors of the Windsor Detroit Bridge Authority, the federal crown corporation overseeing the construction and operation of the $5.7 billion Gordie Howe International Bridge. “We are pleased to welcome Dwight Duncan to the board of Pure Extracts,” said chief executive officer Ben Nikolaevsky. “Dwight has tremendous experience in both government regulatory affairs and corporate finance, and we are looking forward to working closely with him as we build Pure Extracts into a preeminent global extraction company.”

To view the full press release, visit https://ibn.fm/vyB4Z

About Pure Extracts Technologies Corp.

Pure Extracts was incorporated under the BCBCA and has its offices and operations in Pemberton, British Columbia. On September 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act. On November 5, 2020, Pure Extracts began trading on the CSE under the symbol “PULL.” Pure Extracts is undertaking the operations of toll processing, white labelling, and developing its own private label of products incorporating its full spectrum THC and CBD based extracted oils. Additionally, Pure Extracts is presently expanding its business to include functional mushrooms extraction by working on functional mushroom extraction processes compatible with its existing infrastructure. Pure Extracts has a fully built C02 extraction facility built to European Union GMP standards and intends to seek EU GMP certification of its operations allowing it to export its products for sale in Europe where such products are legal. For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Thursday, November 12th, 2020 Uncategorized Comments Off on $PULL Announces Board Appointment of Dwight Duncan

Gage Cannabis Prepares to Capitalize on Stunning Growth Within Michigan’s Cannabis Industry

  • Gage Cannabis, vertically integrated cannabis operator, has stated goals to become fastest-growing cannabis brand in state of Michigan
  • Michigan’s cannabis industry has benefitted from strong growth momentum ever since state passed motion to legalize cannabis for adult recreational use in 2018; sector now valued at estimated $3 billion per annum at maturity
  • Gage Cannabis currently has five retail locations across Michigan along with three wholly-owned cultivation centers all fully operational
  • Company posted $13.1 million in 3Q2020 sales (unaudited), a 129% increase from its 1Q2020 figure of $5.8 million

On December 4, 2018, Michigan officially became the 10th state in the United States to legalize marijuana for adult recreational use. Since then, Gage Cannabis a leading vertically integrated operator in the cannabis industry led by former CEO and Chairman of Canopy Growth Corp. Bruce Linton, has sought to focus on the Michigan market, with the stated ambition of building the fastest-growing cannabis brand in the state.

Gage Cannabis has witnessed a rapid growth trajectory since its inception, having opened its first medical provisioning center (dispensary) in the state of Michigan in 2019. Since then, the company has seen its retail footprint expand to five medical or adult-use locations, with plans to operate 20+ locations by the end of 2021. Gage Cannabis has simultaneously sought to complement its retail distribution network with a swiftly expanding cultivation operation—one which has focused on producing small-batch, indoor-grown, and hand-trimmed plants designed to ensure that every gram of cannabis sold is of the highest quality.

Currently, the company boasts three operational cultivation sites, located at Monitor Township, Harrison Township, and Warren while operating one processing facility located in the Harrison Township. Going forward, the company intends to open a new processing facility located in close proximity to its cultivation assets.

Ever since the use of recreational cannabis was legalized in 2018, Michigan has emerged as one of the fastest-growing legal cannabis markets in the United States in terms of consumption. State authorities have recently projected recreational marijuana sales to be worth nearly $1 billion per annum in 2021 with revenues set to rise above $1.5 billion by 2023 (https://ibn.fm/1PJhv).

Gage Cannabis has sought to capitalize on surging cannabis demand within Michigan through its extensive distribution footprint – one which has seen the company establish a presence encompassing an estimated 90% of Michigan’s population within a one-hour radius of its dispensaries. The company’s initiatives have not gone unrewarded.

Gage Cannabis recorded sales of $5.8 million in 1Q2020—a figure which rose to $11.9 million in 2Q2020 and is forecast to rise further to $13.1mn (unaudited) in 3Q2020 as per management guidance, marking a 129% growth in sales from 1Q2020 to 3Q2020. The increase has been reflected through a commensurate increase in the company’s cultivation capacity, which has risen from 200 pounds per month at the start of the year to an estimated 1,000 pounds by December – with the increase in cultivation capacity assisting the company promote rapid growth through its retail locations.

A study carried out by the Brightfield Group found that the recreational marijuana market in Michigan could be set to rival the figures seen in areas such as Nevada and Colorado by 2023 (https://ibn.fm/VMNJ8). In fact, Michigan is already one of the top five cannabis markets based on the most recent month of cannabis sales. The study found that 3% of Michigan’s residents were medical marijuana cardholders, a figure which has led the consumer insights company to predict that the state’s recreational market could triple in size over the next three years.

Gage Cannabis has recently announced its intentions to raise up to $50 million in gross proceeds through a regulation A+ offering (https://ibn.fm/wPg02), with a portion of the proceeds set to be re-invested to finance the company’s various growth initiatives. With Michigan’s cannabis market set to expand exponentially in the coming years, Gage Cannabis finds itself well-positioned to capitalize on market’s future growth trajectory.

To learn more about the company’s Regulation A financing, visit www.GageInvestors.com.

For more information on Gage Cannabis Co., visit the company’s website at www.GageUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to Gage Cannabis are available in the company’s newsroom at https://ibn.fm/GAGE

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Thursday, November 12th, 2020 Uncategorized Comments Off on Gage Cannabis Prepares to Capitalize on Stunning Growth Within Michigan’s Cannabis Industry
Top Small Cap Market News